Document:

<PAGE>

THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR UNDER ANY APPLICABLE STATE
SECURITIES LAW AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
STATEMENT IS NOT REQUIRED UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS
PROMULGATED THEREUNDER OR UNDER APPLICABLE STATE SECURITIES LAWS.

                               WARRANT CERTIFICATE
                               -------------------

                                                               December 26, 2000

                 To Purchase 600,846 Shares of Common Stock of:

                                 CYTOMEDIX, INC.

     THIS IS TO CERTIFY THAT, for value received, CURATIVE HEALTH SERVICES, INC.
or its assigns (the "Holder"), is entitled to purchase from Cytomedix, Inc., a
Delaware corporation (the "Company"), Six Hundred Thousand, Eight Hundred
Forty-Six (600,846) shares of the Company's common stock, par value $.0001 per
share (the "Common Stock"), on the terms and conditions hereinafter set forth.

I. GRANT OF WARRANT

     1.1 GRANT AND VESTING. The Company hereby grants to the Holder a warrant to
purchase up to 600,846 shares of Common Stock (this "Warrant") at a purchase
price equal to the lesser of $.50 per share of Common Stock, as adjusted as
provided herein (the "Fixed Exercise Price"), or a price per share equal to the
average of the three lowest intraday sale prices as reported by Bloomberg
Financial Markets or an equivalent, reliable reporting service mutually
acceptable to and hereafter designated by the Holder and the Company (as
equitably adjusted for stock splits or combinations or other events referenced
in Article II hereof) during the twenty (20) trading days immediately preceding
the date on which this Warrant is exercised (the "Market Exercise Price"). This
Warrant shall vest as to all 600,846 shares of Common Stock immediately upon the
Holder's funding of the principal sum of $1,682,571 to the Company pursuant to
the terms of that certain 10% Convertible Secured Promissory Note payable by the
Company to Holder dated as of the date hereof (the "Note"). The shares of Common
Stock, or other securities for which this Warrant may be exercised as a result
of transactions contemplated by Article II, are referred to as the "Warrant
Shares." The term "Warrants" shall mean this Warrant and the other warrants
issued pursuant to that certain Securities Purchase Agreement of even date
herewith by and among the Company and the Buyers listed on the signature pages
thereof (the "Securities Purchase Agreement").

<PAGE>

     1.2 EXERCISE PERIOD. This Warrant shall be exercisable commencing on the
date of original issuance of this Warrant (the "Exercisability Date") and
continue to be exercisable for the period (the "Exercise Period") until 5:00
p.m., Eastern Standard Time, on the date that is ten (10) years from the date of
this Warrant.

     1.3 SHARES TO BE ISSUED; RESERVATION OF SHARES. The Company covenants and
agrees that (a) all of the securities issuable upon the exercise of this Warrant
in accordance with the terms hereof will, upon issuance in accordance with the
terms hereof and payment of the Exercise Price therefor, be duly authorized,
validly issued and outstanding, fully paid and non-assessable, and free from all
taxes, liens and charges with respect to the issuance thereof, (b) the Company
will cause during the Exercise Period, there to be authorized and reserved a
sufficient number of securities to provide for the exercise of this Warrant in
full, and (c) the Company shall promptly secure the listing of the shares of
Common Stock issuable upon exercise of the Warrant upon each national securities
exchange or automated quotation system, if any, upon which shares of Common
Stock are then listed (subject to official notice of issuance upon exercise of
this Warrant) and shall maintain, so long as any other shares of Common Stock
shall be so listed, such listing of all shares of Common Stock from time to time
issuable upon the exercise of this Warrant; and the Company shall so list on
each national securities exchange or automated quotation system, as the case may
be, and shall maintain such listing of, any other shares of capital stock of the
Company issuable upon the exercise of this Warrant if and so long as any shares
of the same class shall be listed on such national securities exchange or
automated quotation system.

II. ADJUSTMENTS TO WARRANT

     2.1 STOCK SPLITS AND COMBINATIONS. If the Company shall combine all of its
outstanding shares of Common Stock into a smaller number of shares, the number
of Warrant Shares shall be proportionately decreased and the Fixed Exercise
Price in effect immediately prior to such combination shall be proportionately
increased, as of the effective date of such combination, as follows: (a) the
number of Warrant Shares purchasable immediately prior to the effective date of
such combination shall be adjusted so that the Holder of this Warrant, if
exercised on or after that date, shall be entitled to receive the number and
kind of Warrant Shares which the Holder of this Warrant would have owned and
been entitled to receive as a result of the combination had the Warrant been
exercised immediately prior to that date, and (b) the Fixed Exercise Price in
effect immediately prior to such adjustment shall be adjusted by multiplying
such Fixed Exercise Price by a fraction, the numerator of which is the aggregate
number of shares of Common Stock purchasable upon exercise of this Warrant
immediately prior to such adjustment, and the denominator of which is the
aggregate number of shares of Common Stock purchasable upon exercise of this
Warrant immediately thereafter. If the Company shall subdivide all of its
outstanding shares of Common Stock, the number of Warrant Shares shall be
proportionally increased and the Fixed Exercise Price in effect prior to such
subdivision shall be proportionately decreased, as of the effective date of such
subdivision, as follows: (a) the number of Warrant Shares purchasable upon the
exercise of this Warrant immediately prior to the effective date of such
subdivision, shall be adjusted so that the Holder of this Warrant, if exercised
on or after that date, shall be entitled to receive the number and kind of
Warrant Shares which the Holder of this Warrant would have owned and been
entitled to

                                       2
<PAGE>

receive as a result of the subdivision had the Warrant been exercised
immediately prior to that date, and (b) the Fixed Exercise Price in effect
immediately prior to such adjustment shall be adjusted by multiplying the Fixed
Exercise Price by a fraction, the numerator of which is the aggregate number of
shares of Common Stock purchasable upon exercise of this Warrant immediately
prior to such adjustment, and the denominator of which is the aggregate number
of shares of Common Stock purchasable upon exercise of this Warrant immediately
thereafter. A like and equitable adjustment shall be made in the event that a
stock combination or subdivision is effectuated and the number of Warrant Shares
issued hereunder is to be determined by reference to the Market Exercise Price.

     2.2 STOCK DIVIDENDS AND DISTRIBUTIONS. If the Company shall fix a record
date for the holders of its Common Stock entitled to receive a dividend or other
distribution payable in additional shares of Common Stock, then the number of
Warrant Shares shall be proportionately increased and the Fixed Exercise Price
in effect prior to the time of such issuance or the close of business on such
record date shall be proportionately decreased, as of the time of such issuance,
or in the event such record date is fixed, as of the close of business on such
record date, as follows: (a) the number of Warrant Shares purchasable
immediately prior to the time of such issuance or the close of business on such
record date shall be adjusted so that the Holder of this Warrant, if exercised
after that date, shall be entitled to receive the number and kind of Warrant
Shares which the Holder of this Warrant would have owned and been entitled to
receive as a result of the dividend or distribution had the Warrant been
exercised immediately prior to that date, and (b) the Fixed Exercise Price in
effect immediately prior to such adjustment shall be adjusted by multiplying
such Fixed Exercise Price by a fraction, the numerator of which is the aggregate
number of shares of Common Stock purchasable upon exercise of this Warrant
immediately prior to such adjustment, and the denominator of which is the
aggregate number of shares of Common Stock purchasable upon exercise of this
Warrant immediately thereafter. A like and equitable adjustment shall be made in
the event that a stock dividend or distribution is effectuated and the number of
Warrant Shares issued hereunder is to be determined by reference to the Market
Exercise Price.

     2.3 OTHER DIVIDENDS AND DISTRIBUTIONS. If the Company shall fix a record
date for the holders of Common Stock entitled to receive a dividend or other
distribution payable in securities of the Company other than shares of Common
Stock, then lawful and adequate provision shall be made so that the Holder of
this Warrant shall be entitled to receive upon exercise of this Warrant, for the
applicable exercise price in effect prior thereto, in addition to the number of
Warrant Shares immediately theretofore issuable upon exercise of this Warrant,
the kind and number of securities of the Company which the Holder would have
owned and been entitled to receive had the Warrant been exercised immediately
prior to that date.

     2.4 RECLASSIFICATION, EXCHANGE AND SUBSTITUTION. If the Common Stock is
changed into the same or a different number of shares of any class or classes of
stock, whether by recapitalization, reclassification or otherwise (other than by
a subdivision or combination of shares or stock dividend or a reorganization,
merger, consolidation or sale of assets provided for elsewhere in this Article
II), then the Holder of this Warrant shall be entitled to receive upon exercise
of this Warrant, in lieu of the Warrant Shares immediately theretofore issuable
upon exercise of this Warrant, for the aggregate exercise price in effect prior
thereto, the kind and amount of stock and other securities and property
receivable upon such recapitalization, reclassification or other change, by the
holders of the number

                                       3
<PAGE>

of shares of Common Stock for which the Warrant could have been exercised
immediately prior to such recapitalization, reclassification or other change (in
any event, subject to further anti-dilution protection as provided in this
Section 2).

     2.5 REORGANIZATIONS, MERGERS, CONSOLIDATIONS OR SALES OF ASSETS. If any of
the following transactions (each, a "Special Transaction") shall become
effective: (a) a capital reorganization, share exchange or exchange offer (other
than a recapitalization, subdivision, combination, reclassification or exchange
of shares provided for elsewhere in this Article II), (b) a consolidation or
merger of the Company with and into another entity, or (c) a sale or conveyance
of all or substantially all of the Company's assets, then as a condition of any
Special Transaction, lawful and adequate provision shall be made so that the
Holder of the Warrant shall thereafter have the right to purchase and receive
upon exercise of this Warrant, in lieu of the Warrant Shares immediately
theretofore issuable upon exercise of this Warrant, for the applicable exercise
price in effect immediately prior to such event, such shares of stock, other
securities, cash or other assets as may be issued or payable in and pursuant to
the terms of such Special Transaction to the holders of shares for which this
Warrant could have been exercised immediately prior to such Special Transaction;
provided, however, that notwithstanding anything to the contrary herein, that
upon consummation of the transactions contemplated by the Exchange Agreement (as
defined below), this Warrant shall be exercisable for shares of common stock of
Cytomedix NV. In connection with any Special Transaction, appropriate provision
shall be made with respect to the rights and interests of the Holder of this
Warrant to the end that the provisions of this Warrant (including, without
limitation, provisions for adjustment of the applicable exercise price and the
number of Warrant Shares issuable upon the exercise of this Warrant), shall
thereafter be applicable, as nearly as may be practicable, to any shares of
stock, other securities, cash or other assets thereafter deliverable upon the
exercise of this Warrant. The Company shall not effect any Special Transaction
unless prior to, or simultaneously with the closing thereof, the successor
entity and the issuer of the securities into which this Warrant is exercisable
(if other than the Company), if any, resulting from such Special Transaction
shall assume by a written instrument executed and mailed by certified mail or
delivered to the Holder of this Warrant at the address of the Holder appearing
on the books of the Company, the obligation of the Company or such successor
corporation to deliver to the Holder such shares of stock, securities, cash or
other assets, as in accordance with the foregoing provisions, which the Holder
shall have the right to purchase.

     2.6 OTHER ISSUANCES. In the event that the Company shall at any time after
the Exercisability Date issue any shares of Common Stock, including shares of
Common Stock issued or issuable upon the conversion or exercise of securities
convertible into or exercisable for Common Stock, without consideration or at a
price per share ("Issuance Price") less than the then applicable exercise price,
then, in each and any such event (an "Adjustment Event"), (a) the number of
Warrant Shares purchasable immediately prior thereto (the "Initial Number")
shall be increased so that the Holder shall be entitled, upon exercise of this
Warrant, to receive the number of shares of Common Stock determined by
multiplying the Initial Number by a fraction, the numerator of which shall be
the number of shares of Common Stock outstanding immediately prior to such
Adjustment Event plus the number of additional shares of Common Stock issued in
such Adjustment Event and the denominator of which shall be the number of shares
of Common Stock outstanding immediately

                                       4
<PAGE>

prior to such Adjustment Event plus the number of shares of Common Stock which
the aggregate Issuance Price of the total number of shares of Common Stock
issued in such Adjustment Event would purchase at the then applicable exercise
price; provided, however, that no adjustment shall be made for the issuance of
shares of Common Stock in connection with a Special Transaction, as described in
Section 2.5; and the applicable Fixed Exercise Price shall be reduced to the
Issuance Price.

     2.7 LIQUIDATION. If the Company shall, at any time prior to the end of the
Exercise Period, dissolve, liquidate or wind up its affairs, the Holder shall
have the right, but not the obligation, to exercise this Warrant. Upon such
exercise, the Holder shall have the right to receive, in lieu of the shares of
Common Stock that the Holder otherwise would have been entitled to receive upon
such exercise, the same kind and amount of assets as would have been issued,
distributed or paid to the Holder upon any such dissolution, liquidation or
winding up with respect to such shares of Common Stock had the Holder been the
holder of record of such shares of Common Stock receivable upon exercise of this
Warrant on the date for determining those entitled to receive any such
distribution. If any such dissolution, liquidation or winding up results in any
cash distribution in excess of the applicable exercise price, the Holder may, at
the Holder's option, exercise this Warrant without making payment of the
applicable exercise price and, in such case, the Company shall, upon
distribution to the Holder, consider the applicable exercise price, to have been
paid in full, and in making settlement to the Holder shall deduct an amount
equal to the applicable exercise price, from the amount payable to the Holder.

     2.8 NOTICE. Whenever this Warrant or the number of Warrant Shares is to be
adjusted as provided herein, the Company shall forthwith as soon as reasonably
practicable, and in any case within three (3) business days of such adjustment,
and in any case within three (3) business days of such adjustment, cause to be
sent to the Holder a notice stating in reasonable detail the relevant facts and
any resulting adjustments and the calculation thereof.

     2.9 FRACTIONAL INTERESTS. The Company shall not be required to issue
fractions of shares of Common Stock upon the exercise of this Warrant. If any
fraction of a share of Common Stock would be issuable upon the exercise of this
Warrant, the Company shall, upon such issuance, purchase such fraction for an
amount in cash equal to the current value of such fraction, computed on the
basis of the last reported closing price of the Common Stock on the securities
exchange or quotation system on which the shares of Common Stock are then listed
or traded, as the case may be, if any, on the last business day prior to the
date of exercise upon which such a sale shall have been effected, or, if the
Common Stock is not so listed or traded on an exchange or quotation system, as
the Board of Directors of the Company may in good faith determine.

     2.10 EFFECT OF ALTERNATE SECURITIES. If at any time, as a result of an
adjustment made pursuant to this Article II, the Holder of this Warrant shall
thereafter become entitled to receive any securities of the Company other than
shares of Common Stock, then the number of such other securities receivable upon
exercise of this Warrant shall be subject to adjustment from time to time on
terms as nearly equivalent as practicable to the provisions with respect to
shares of Common Stock contained in this Article II.

                                       5
<PAGE>

     2.11 SUCCESSIVE APPLICATION. The provisions of this Article II shall apply
from time to time to successive events covered by this Article II. Upon the
occurrence of any event contemplated by this Article II, all references to
Common Stock, to the Company and to other defined terms shall be equitably
adjusted to protect the interests of the Holder.

     2.12 OTHER NOTICES. In case at any time:

         (I) the Company shall declare any dividend upon the Common Stock
payable in shares of stock of any class or make any other distribution
(including dividends or distributions payable in cash out of retained earnings)
to the holders of the Common Stock;

         (II) the Company shall offer for subscription pro rata to the holders
of the Common Stock any additional shares of stock of any class or other rights;

         (III) there shall be any capital reorganization of the Company, or
reclassification of the Common Stock, or consolidation or merger of the Company
with or into, or sale of all or substantially all its assets to, another
corporation or entity; or

         (IV) there shall be a voluntary or involuntary dissolution, liquidation
or winding-up of the Company;

then, in each such case, the Company shall give to the holder of this Warrant
(a) notice of the date on which the books of the Company shall close or a record
shall be taken for determining the holders of Common Stock entitled to receive
any such dividend, distribution, or subscription rights or for determining the
holders of Common Stock entitled to vote in respect of any such reorganization,
reclassification, consolidation, merger, sale, dissolution, liquidation or
winding-up and (b) in the case of any such reorganization, reclassification,
consolidation, merger, sale, dissolution, liquidation or winding-up, notice of
the date (or, if not then known, a reasonable approximation thereof by the
Company) when the same shall take place. Such notice shall also specify the date
on which the holders of Common Stock shall be entitled to receive such dividend,
distribution, or subscription rights or to exchange their Common Stock for stock
or other securities or property deliverable upon such reorganization,
reclassification, consolidation, merger, sale, dissolution, liquidation, or
winding-up, as the case may be. Such notice shall be given at least twenty (20)
business days prior to the record date or the date on which the Company's books
are closed in respect thereto. Failure to give any such notice or any defect
therein shall not affect the validity of the proceedings referred to in clauses
(i), (ii), (iii) and (iv) above.

     2.13 EXCEPTION TO ADJUSTMENTS. Notwithstanding anything herein or in any
Note to the contrary, no adjustment to the Fixed Exercise Price shall be made
with respect to the issuance of securities by the Company, all of the net
proceeds of which are used to repurchase, in whole or in part, the Notes as
contemplated by Section 4(e) of the Purchase Agreement (an "Exempt Issuance"),
provided that the Holder receives an adjustment to the Fixed Exercise Price to
the extent that any options or warrants are issued in connection with such
Exempt Issuance. For example, if warrants to purchase 10,000 shares of Common
Stock are issued in connection with the Exempt Issuance at a

                                       6
<PAGE>

conversion price of $0.10, then a total of 10,000 of the shares of Common Stock
otherwise issuable to each of the holders of warrants issued in connection with
the Purchase Agreement (including, without limitation, the Holder) at the
exercise price provided for herein shall have a Fixed Exercise Price of $0.10.
As among the holders, the shares of Common Stock issuable to such holders
pursuant to this Section 2.13 shall be allocated among such holders pro rata in
accordance with the respective number of shares of Common Stock otherwise
issuable to the holders pursuant to such warrants.

III. EXERCISE

     3.1 EXERCISE OF WARRANT.

         (a) The Holder may exercise this Warrant by (i) surrendering this
Warrant Certificate with the form of exercise notice attached hereto as Exhibit
"A" duly executed by the Holder, and (ii) making payment to the Company of the
aggregate Exercise Price for the applicable Warrant Shares in cash, by certified
check or wire transfer of immediately available funds to an account designated
by the Company. Upon any partial exercise of this Warrant, the Company, at its
expense, shall promptly issue to the Holder for its surrendered Warrant
Certificate a replacement Warrant Certificate identical in all respects to this
Warrant Certificate, except that the number of Warrant Shares shall be reduced
accordingly.

         (b) Notwithstanding anything in this Warrant to the contrary, in no
event shall the holder of this Warrant be entitled to exercise a number of
Warrants (or portions thereof) in excess of the number of Warrants (or portions
thereof) upon exercise of which the sum of (i) the number of shares of Common
Stock beneficially owned by the holder and its affiliates (other than shares of
Common Stock which may be deemed beneficially owned through the ownership of the
unexercised Warrants and the unexercised or unconverted portion of any other
securities of the Company (including the Notes (as defined in the Securities
Purchase Agreement)) subject to a limitation on conversion or exercise analagous
to the limitation contained herein) and (ii) the number of shares of Common
Stock issuable upon exercise of the Warrants (or portions thereof) with respect
to which the determination described herein is being made, would at the time of
exercise result in beneficial ownership by the holder and its affiliates of more
than 4.9% of the outstanding shares of Common Stock. For purposes of the
immediately preceding sentence, beneficial ownership shall be determined in
accordance with Section 13(d) of the Securities Exchange Act of 1934, as
amended, and Regulation 13D-G thereunder, except as otherwise provided in clause
(i) of the preceding sentence. Notwithstanding anything to the contrary
contained herein, the limitation on exercise of this Warrant set forth herein
may not be amended without (i) the written consent of the holder hereof and the
Company and (ii) the approval of a majority of shareholders of the Company.

         (c) Each person in whose name any Warrant Share certificate is issued
upon exercise of this Warrant shall for all purposes been deemed to have become
the holder of record of the Warrant Shares for which this Warrant was exercised
as of the date of exercise. Certificates for the Warrant Shares so purchased,
representing the aggregate number of shares specified in the Exercise Agreement,
shall be delivered to the holder hereof within a reasonable time, not exceeding
three (3) business days, after this Warrant shall have been so exercised. The
certificates so delivered

                                       7
<PAGE>

shall be in such denominations as may be requested by the holder hereof and
shall be registered in the name of such holder or such other name as shall be
designated by such holder. If this Warrant shall have been exercised only in
part, then, unless this Warrant has expired, the Company shall, at its expense,
at the time of delivery of such certificates, deliver to the holder a new
Warrant representing the number of shares with respect to which this Warrant
shall not then have been exercised. In addition to all other available remedies
at law or in equity, if the Company fails to deliver certificates for the
Warrant Shares within four (4) business days after this Warrant is exercised,
then the Company shall pay to the holder in cash a penalty (the "Penalty") equal
to 2% of the number of Warrant Shares that the Holder is entitled to multiplied
by the Market Price for each day that the Company fails to deliver certificates
for the Warrant Shares. For example, if the Holder is entitled to 100,000
Warrant Shares and the Market Price is $2.00, then the Company shall pay to the
Holder $4,000 for each day that the Company fails to deliver certificates for
the Warrant Shares. The Penalty shall be paid to the Holder by the fifth day of
the month following the month in which it has accrued.

     3.2 ISSUANCE OF WARRANT SHARES. The Warrant Shares purchased shall be
issued to the Holder exercising this Warrant as of the close of business on the
business day on which all actions and payments required to be taken or made by
the Holder hereunder shall have been so taken or made. Certificates for the
Warrant Shares so purchased shall be delivered to the Holder as soon as
reasonably practicable after this Warrant is so exercised.

     3.3 CASHLESS EXERCISE. Notwithstanding any provisions herein to the
contrary, in lieu of exercising this Warrant by paying the Exercise Price in the
manner set forth in Section 3.1(a), prior to its expiration pursuant to Section
1.2, the Holder may, by providing notice thereof to the Company along with the
Notice of Exercise, elect to exercise the Warrant for a reduced number of
Warrant Shares determined in accordance with the following formula:

                                   X = Y(A-B)
                                       ------
                                         A

Where:

         X = The number of Warrant Shares to be issued to the Holder.

         Y = The number of Warrant Shares purchasable under this Warrant (at the
         date of such exercise).

         A = The fair market value of one share of Common Stock (or other
         security for which the Warrant is then exercisable at the date of such
         exercise).

         B = Exercise Price (as adjusted to the date of such exercise).

             For purposes of this Section 3.3, the "fair market value" per share
shall be, in the event the Warrant is being exercised at the time the Company's
Common Stock is listed on a national securities exchange or admitted to unlisted
trading privileges on any such exchange or listed for trading on the Nasdaq
Stock Market, the last reported sale price of Common Stock on such exchange

                                       8
<PAGE>

or system on the last business day prior to the date of exercise of the Warrant
(or if no such sale is made on such day, the average of the closing bid and ask
prices for Common Stock for such day on such exchange or system), or otherwise
shall be determined in such reasonable manner as may be prescribed in good faith
by the Company's Board of Directors.

IV. RIGHTS OF THE HOLDER

     4.1 NO RIGHTS OR LIABILITIES AS SHAREHOLDER. Except as provided herein, the
Holder shall not, solely by virtue of this Warrant and prior to the issuance of
the Warrant Shares upon due exercise hereof, be entitled to any rights as a
shareholder of the Company. No provision of this Warrant, in the absence of
affirmative action by the holder hereof to purchase Warrant Shares, and no mere
enumeration herein of the rights or privileges of the holder hereof, shall give
rise to any liability of such holder for the Exercise Price or as a shareholder
of the Company, whether such liability is asserted by the Company or by
creditors of the Company.

     4.2 CERTAIN COVENANTS. The Company will (a) take all such action as may be
necessary or appropriate in order that the Warrant Shares will, upon issuance in
accordance with the terms hereof and the payment of the Exercise Price therefor,
be duly authorized, validly issued and outstanding, fully paid and
non-assessable and (b) use its reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having
jurisdiction thereof as may be necessary to enable the Company to perform its
obligations under this Warrant. The Company will not, by amendment of its
charter or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms to be
observed or performed by it hereunder, but will at all times in good faith
assist in the carrying out of all the provisions of this Warrant and in the
taking of all such action as may reasonably be requested by the holder of this
Warrant in order to protect the exercise privilege of the holder of this Warrant
against dilution or other impairment, consistent with the tenor and purpose of
this Warrant. Without limiting the generality of the foregoing, the Company (i)
will not increase the par value of any shares of Common Stock receivable upon
the exercise of this Warrant above the Exercise Price then in effect, and (ii)
will take all such actions as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable shares of
Common Stock upon the exercise of this Warrant in accordance with the terms
hereof and payment of the Exercise Price therefor.

                                       9
<PAGE>

V. LOSS

     Upon receipt by the Company of evidence reasonably satisfactory to it of
the loss, theft, destruction or mutilation of this Warrant, and (in the case of
loss, theft or destruction) reasonably satisfactory indemnification, and upon
surrender and cancellation of this Warrant, if mutilated, the Company shall
immediately execute and deliver a new Warrant of like tenor and date.

VI. LEGEND ON WARRANT SHARES

     6.1 LEGEND. The certificates representing the Warrant Shares shall bear a
legend substantially similar to the following:

         "The securities represented by this certificate have not been
         registered under the Securities Act of 1933, as amended (the "Act") or
         under applicable state securities laws, and may not be offered or sold
         except (1) pursuant to an effective registration statement under the
         Act or (2) upon the delivery by the holder to the Company of an opinion
         of counsel reasonably satisfactory to the Company that such
         registration statement is not required under the Securities Act and the
         rules and regulations promulgated thereunder or under applicable state
         securities laws."

VII. REGISTRATION RIGHTS

     7.1 REGISTRATION RIGHTS AGREEMENT. The Holder shall be entitled to
registration rights pursuant to the terms of that certain Registration Rights
Agreement between the Company and the signatories thereto (the "Registration
Rights Agreement") of even date herewith.

     7.2 EXCHANGE AGREEMENT. Upon consummation of the Exchange Agreement, all
obligations of the Company under the Registration Rights Agreement shall become
obligations of Cytomedix NV.

     7.3 FAILURE TO MEET OBLIGATIONS. If the Company shall fail to prepare and
file the Registration Statement (as defined in the Registration Rights
Agreement) within forty-five (45) days of the date hereof, then the Fixed
Exercise Price shall be reduced to $0.01 per Warrant Share.

VIII. MISCELLANEOUS

     8.1 REPRESENTATIONS OF THE COMPANY. The Company represents and warrants to
the Holder as follows:

         (a) The execution and delivery of this Warrant and the performance by
the Company of its obligations hereunder have been duly authorized by all
necessary corporate action on part of the Company in accordance with its Bylaws
and Articles of Incorporation.

         (b) This Warrant has been duly executed and delivered by the Company
and constitutes the legal, valid, binding and enforceable obligation of the
Company, enforceable in

                                       10
<PAGE>

accordance with its terms, except as such enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally, the enforcement of creditors'
rights and remedies or by other equitable principles of general application.

         (c) Upon issuance thereof in accordance with the terms hereof and
payment of the Exercise Price therefor, all of the Shares will, upon issuance,
be duly authorized, validly issued and outstanding, fully paid and
non-assessable, and free from all taxes, liens and charges with respect to the
issuance thereof.

         (d) Except for filings under applicable state and federal securities
laws, the Company has obtained all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations hereunder.

         (e) There are no state statutes or other "anti-takeover" laws
applicable to the Company, to the issuance of this Warrant by the Company, or to
the issuance of the Warrant Shares upon exercise of this Warrant which would
have, among other things, the effect of nullifying the transactions contemplated
by this Warrant, or affecting the Holder's voting rights or other rights as a
shareholder following such exercise, or to the extent there are such applicable
state statutes or other "anti-takeover" laws, the Company and its Board of
Directors have taken all steps necessary under such statutes or laws to render
them inapplicable to the Company, the issuance of this Warrant, and the issuance
of the Warrant Shares upon exercise of this Warrant.

         (f) There is no litigation pending, or, to the knowledge of the
Company, threatened, against the Company which, if adversely decided or
resolved, would have a Material Adverse Effect, as defined in the Purchase
Agreement.

     8.2 ASSIGNMENT. The rights, obligations and duties of the Company hereunder
shall not be assignable or otherwise transferable by the Company. This Warrant
and the rights granted to the holder hereof are transferable by the Holder, in
whole or in part, upon surrender of this Warrant, together with a properly
executed assignment in the form attached hereto, at the office or agency of the
Company.

         If, at the time of the surrender of this Warrant in connection with any
exercise, transfer, or exchange of this Warrant, this Warrant (or, in the case
of any exercise, the Warrant Shares issuable hereunder), shall not be registered
under the Securities Act of 1933, as amended (the "Securities Act") and under
applicable state securities or blue sky laws, the Company may require, as a
condition of allowing such exercise, transfer, or exchange, (i) that the holder
or transferee of this Warrant, as the case may be, furnish to the Company a
written opinion of counsel, which opinion and counsel are acceptable to the
Company, to the effect that such exercise, transfer, or exchange may be made
without registration under said Act and under applicable state securities or
blue sky laws, (ii) that the holder or transferee execute and deliver to the
Company an investment letter in form and substance acceptable to the Company and
(iii) that the transferee be an "accredited investor" as defined in Rule 501(a)
of Regulation D promulgated

                                       11
<PAGE>

under the Securities Act; provided that no such opinion, letter or status as an
"accredited investor" shall be required in connection with a transfer pursuant
to Rule 144 under the Securities Act. The first holder of this Warrant, by
taking and holding the same, represents to the Company that such holder is
acquiring this Warrant for investment and not with a view to the distribution
thereof.

         8.3 MODIFICATION. No term or provision contained herein may be
modified, amended or waived except by written agreement or consent signed by the
party to be bound thereby.

         8.4 BINDING EFFECT AND BENEFIT. This warrant shall inure to the benefit
of, and shall be binding upon, the parties hereto, their heirs, executors,
administrators, personal representatives, successors in interest and permitted
assigns.

         8.5 ATTORNEYS' FEES. In the event the Holder shall employ legal counsel
to protect its rights hereunder or to enforce any term or provision hereof or
under any of the Loan Documents (as defined in the "Note"), such reasonable
attorneys' fees and other legal expenses shall be payable by Company to the
Holder upon demand. The Company shall pay all fees and expenses of the Holder in
connection with the negotiation and consummation of this Warrant and the Loan
Documents.

         8.6 FURTHER ASSURANCES. Company agrees that from time to time
hereafter, upon request, it will, at its sole expense, execute, acknowledge and
deliver such other instruments and documents and take such further action as may
be reasonably necessary to carry out the intent of this warrant and the Loan
Documents.

         8.7 GOVERNING LAW; WAIVER OF JURY TRIAL. THIS WARRANT SHALL BE
INTERPRETED, AND THE RIGHTS AND LIABILITIES OF THE PARTIES HERETO DETERMINED, IN
ACCORDANCE WITH THE INTERNAL LAWS (AS OPPOSED TO CONFLICTS OF LAW PROVISIONS) OF
THE STATE OF ILLINOIS. AS PART OF THE CONSIDERATION FOR NEW VALUE THIS DAY
RECEIVED, THE COMPANY HEREBY CONSENTS TO THE JURISDICTION OF ANY STATE OR
FEDERAL COURT LOCATED IN CHICAGO, ILLINOIS. EACH OF THE COMPANY AND THE HOLDER
HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY SUIT OR
PROCEEDING ARISING OUT OF OR RELATED TO THIS WARRANT OR THE OTHER LOAN
DOCUMENTS. THE COMPANY WAIVES ANY OBJECTION WHICH THE COMPANY MAY HAVE BASED ON
LACK OF JURISDICTION OR IMPROPER VENUE OR FORUM NON CONVENIENS TO ANY SUIT OR
PROCEEDING INSTITUTED BY THE HOLDER UNDER THIS WARRANT OR THE OTHER LOAN
DOCUMENTS IN ANY STATE OR FEDERAL COURT LOCATED IN CHICAGO, ILLINOIS AND
CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED
APPROPRIATE BY THE COURT. NOTHING IN THIS SECTION SHALL AFFECT THE RIGHT OF THE
HOLDER TO BRING ANY ACTION OR PROCEEDING AGAINST THE COMPANY OR ITS PROPERTY IN
THE COURTS OF ANY OTHER JURISDICTION WHICH HAS JURISDICTION OVER THE COMPANY OR
ITS PROPERTY. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE HOLDER TO ENTER
INTO THIS WARRANT AND THE OTHER LOAN DOCUMENTS,

                                       12
<PAGE>

MAKE THE LOANS AND EXTEND THE OTHER FINANCIAL ACCOMMODATIONS CONTEMPLATED
HEREUNDER AND THEREUNDER.

         8.8 INCORPORATION BY REFERENCE. All exhibits and documents referred to
in this agreement shall be deemed incorporated herein by any reference thereto
as if fully set out.

         8.9 COUNTERPARTS. This agreement may be executed in one or more
counterparts (all counterparts together reflecting the signature of all parties)
each of which shall be deemed an original, and all of which together shall
constitute one and the same instrument.

         8.10 CONSENT TO JURISDICTION AND SERVICE OF PROCESS. Company hereby
irrevocably (i) consents to the jurisdiction of the courts of the State of
Illinois and of any federal court located in Illinois in connection with any
action or proceeding arising out of or relating to this agreement, or any other
document or exhibit relating hereto or delivered in connection therewith and
(ii) consents that service of legal process in any such action or proceeding may
be made in any manner permitted by the rules of practice and procedure
applicable to such courts.

         8.11 INDEMNIFICATION OF THE HOLDER. From and at all times after the
date of this Warrant, and in addition to all of the Holder's other rights and
remedies against the Company, the Company agrees to hold the Holder harmless
from, and to indemnify the Holder against, all losses, damages, costs and
expenses (including, but not limited to, attorneys' fees, costs and expenses)
incurred by the Holder from and after the date hereof, whether direct, indirect
or consequential, as a result of or arising from or relating to any suit, action
or proceeding by any Person, whether threatened or initiated, asserting a claim
for any legal or equitable remedy against any Person under any statute or
regulation, including, but not limited to, any federal or state securities laws,
or under any common law or equitable cause or otherwise, arising from or in
connection with the negotiation, preparation, execution or performance of, this
Warrant and the other Loan Documents; provided, however, that the foregoing
indemnification shall not protect Holder from loss, damage, cost or expense
directly attributable to Holder's willful misconduct or gross negligence. All of
the foregoing losses, damages, costs and expenses of the Holder shall be payable
by the Company upon demand by the Holder.

         8.12 SURVIVAL OF AGREEMENTS. All agreements, covenants, representations
and warranties contained herein or made in writing by or on behalf of the
Company in connection with the transactions contemplated hereby shall survive
the execution and delivery of this Warrant and the other Loan Documents.

         8.13 HEADINGS AND CAPTIONS. Subject headings and captions are included
for convenience purposes only and shall not affect the interpretation of this
agreement.

         8.14 NOTICE. All notices, requests, demands and other communications
permitted or required hereunder shall be in writing, and either (i) delivered in
person, (ii) sent by express mail or other overnight delivery service providing
receipt of delivery, (iii) mailed by certified or registered mail, postage
prepaid, return receipt requested or (iv) sent by telex, telegraph or other
facsimile transmission as follows:

                                       13
<PAGE>

     If to Company addressed or delivered in person to:

         Cytomedix, Inc.
         Three Parkway North, Suite 250 North
         Deerfield, IL  60015
         Attention:  President
         Telephone:  847-405-7800
         Facsimile:   847-405-7801

     With a copy to:

         Latham & Watkins
         1001 Pennsylvania Avenue, N.W.
         Suite 1300
         Washington, DC  20004-2505
         Attention:  Stuart Kurlander, Esq.
         Telephone:  202-637-2200
         Facsimile:  202-637-2201

     If to the Holder, addressed or delivered in person to:

         Curative Health Services, Inc.
         150 Motor Parkway
         Happaugue, New York 11788
         Attention:  William Tella
         Sr. Vice President of Business Development
         Telephone:  631-232-7000
         Facsimile:  631-233-8102

     With a copy to:

         Dorsey & Whitney LLP
         250 Park Avenue
         New York, New York  10177
         Attention:  Seth Truwit, Esq.
         Telephone:  212-415-9200
         Facsimile:  212-953-7201

or to such other address as either party may designate by notice in accordance
with this Section.

         Any such notice or communication, if given or made by prepaid,
registered or certified mail or by recorded express delivery, shall be deemed to
have been made when actually received, but not later than three (3) business
days after the same was properly posted or given to

                                       14
<PAGE>

such express delivery service and if made properly by telex, telecopy or other
facsimile transmission such notice or communication shall be deemed to have been
made at the time of dispatch.

     8.15 SEVERABILITY. If any portion of this agreement is held invalid,
illegal or unenforceable, such determination shall not impair the enforceability
of the remaining terms and provisions herein, which may remain effective, and to
this end this agreement is declared to be severable.

     8.16 TIME FOR PERFORMANCE. Time is of the essence in this agreement.

     8.17 WAIVER. No waiver of a default, breach or other violation of any
provision of this agreement shall operate or be construed as a waiver of any
subsequent default, breach or other violation or limit or restrict any right or
remedy otherwise available. No delay or omission on the part of the Holder to
exercise any right or power arising by reason of a default shall impair any such
right or power or prevent its exercise at any time during the continuance
thereof.

     8.18 GENDER AND PRONOUNS. Throughout this agreement, the masculine shall
include the feminine and neuter and the singular shall include the plural and
vice versa as the context requires.

     8.19 ENTIRE AGREEMENT. This Warrant and the Loan Documents constitute the
entire agreement of the parties and supersede any and all other prior
agreements, oral or written, with respect to the subject matter contained
herein.

     8.20 REMEDIES. The Company acknowledges that a breach by it of its
obligations hereunder will cause irreparable harm to the holder, by vitiating
the intent and purpose of the transaction contemplated hereby. Accordingly, the
Company acknowledges that the remedy at law for a breach of its obligations
under this Warrant will be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Warrant, that the
holder shall be entitled, in addition to all other available remedies at law or
in equity, and in addition to the penalties assessable herein, to an injunction
or injunctions restraining, preventing or curing any breach of this Warrant and
to enforce specifically the terms and provisions thereof, without the necessity
of showing economic loss and without any bond or other security being required.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       15
<PAGE>

     IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed
and delivered as of the 26th day of December, 2000.

                                     CYTOMEDIX, INC.

                                     By: /s/ Robin Lee Geller
                                        ------------------------------------
                                        Name:  Robin Lee Geller
                                        Title: Vice President

ATTEST:

/s/ David C. Demarest
---------------------------

                                       16
<PAGE>

                                    EXHIBIT A
                                    ---------

                                 EXERCISE NOTICE

                 [To be executed only upon exercise of Warrant]

         The undersigned registered owner of this Warrant irrevocably exercises
this Warrant for the purchase of the number of shares of Common Stock of
Cytomedix, Inc. as is set forth below, and herewith makes payment therefor, all
at the price and on the terms and conditions specified in the attached Warrant
Certificate and requests that certificates for the shares of Common Stock hereby
purchased (and any securities or other property issuable upon such exercise) be
issued in the name of and delivered to the person specified below whose address
is set forth below, and, if such shares of Common Stock shall not include all of
the shares of Common Stock now and hereafter issuable as provided in the
attached Warrant Certificate, then Cytomedix, Inc. shall, at its own expense,
promptly issue to the undersigned a new Warrant Certificate of like tenor and
date for the balance of the shares of Common Stock issuable thereunder.

Date:
     --------------------

Amount of Shares Purchased:
                           ------------------

Aggregate Purchase Price: $
                           ------------------

Printed Name of Registered Holder:
                                  ---------------------------------

Signature of Registered Holder:
                               ------------------------------------

NOTICE:  The signature on this Exercise Notice must correspond with the name as
         written upon the face of the attached Warrant Certificate in every
         particular, without alteration or enlargement or any change whatsoever.

Stock Certificates to be issued and registered in the following name, and
delivered to the following address:

                                    -----------------------------------
                                    (Name)

                                    -----------------------------------
                                    (Street Address)

                                    -----------------------------------
                                    (City)          (State)  (Zip Code)

                                       17
<PAGE>

                                   ASSIGNMENT

         FOR VALUE RECEIVED, the undersigned hereby sells, assigns, and
transfers all the rights of the undersigned under the within Warrant, with
respect to the number of shares of Common Stock covered thereby set forth
hereinbelow, to:

Name of Assignee                    Address                        No of Shares
----------------                    -------                        ------------

, and hereby irrevocably constitutes and appoints ____________________________as
agent and attorney-in-fact to transfer said Warrant on the books of the
within-named corporation, with full power of substitution in the premises.

Dated:                , 200
      -----------  ---     --

In the presence of:
                                          ----------------------------------

                                     Name:
                                          ----------------------------------

                                     Signature:
                                               -----------------------------
                                     Title of Signing Officer or Agent (if any):

                                               -----------------------------

                                     Address:
                                             -------------------------------

                                             -------------------------------

                                         Note:  The above signature should
                                                correspond exactly with the name
                                                on the face of the within
                                                Warrant, if applicable.

                                       18<PAGE>

                                SUPPLY AGREEMENT

                  This Supply Agreement (the "Agreement"), is made and entered
into as of December 26, 2000 (the "Effective Date"), by and between Cytomedix,
Inc. a Delaware corporation ("Cytomedix"), and Curative Health Services, Inc., a
Minnesota corporation ("Curative").

                                    RECITALS

                  WHEREAS, Cytomedix and Curative are parties to that certain
Amended and Restated Asset Purchase Agreement effective as of October 12, 2000
(the "Asset Purchase Agreement"), pursuant to which Cytomedix has agreed to
purchase certain assets of Curative and its Affiliates as set forth therein; and

                  WHEREAS, pursuant to Section 2.7(a)(x) of the Asset Purchase
Agreement, it is a condition to the closing of the transactions described in the
Asset Purchase Agreement that the parties hereto enter into this Agreement;

                                    AGREEMENT

                  NOW, THEREFORE, for and in consideration of the premises and
the mutual covenants contained herein, and for other good and valuable
consideration, the receipt, adequacy and legal sufficiency of which are hereby
acknowledged, the parties do hereby agree as follows:

                                   ARTICLE I.
                                   DEFINITIONS

                  For purposes of this Agreement, the following terms and
variations thereof have the meanings specified or referred to in this Article I:

                  "Affiliates" - any person or entity which directly or
indirectly controls, is controlled by, or is under common control with a party
hereto. For purposes of this Agreement, "control" shall mean the legal,
beneficial or equitable ownership directly or indirectly of more than fifty
percent (50%) of the aggregate of all voting equity interests rights in such
entity.

                  "Best Efforts" - the efforts that a prudent person desirous of
achieving a result would use in similar circumstances to ensure that such result
is achieved as expeditiously as possible; provided, however, that a person
required to use Best Efforts under this Agreement will not be required to
dispose of or make any change to its business, or expend any material funds or
incur any other material burden.

                  "Blood Processing Facilities Costs and Expenses" - the direct
Facility-specific costs and expenses associated with the operation of the
Facilities and the production of Procuren.

                  "Clinical Trial" - any clinical trial conducted by Cytomedix
in connection with its efforts to receive FDA approval of Procuren or its
ongoing development efforts with respect to Procuren.

                  "Excluded Facilities" - the blood processing facilities
located in Oregon, Maryland, Iowa, and New Hampshire.

                  "Facilities" - the blood processing facilities to be owned and
operated by Seller in the Procuren States as listed on Schedule A attached
hereto, but excluding the Excluded Facilities.

                                       1
<PAGE>

                  "Facility Lease Costs " - the rent payable by Cytomedix for
any portion of the period for which it is not occupying the Facility under any
Seller Lease as in effect as of the date hereof with respect to which (i) a
consent to assignment has not been obtained at Closing (as defined in the Asset
Purchase Agreement), (ii) the lessor has delivered a notice to vacate or similar
instrument and (iii) Cytomedix has relocated from such Facility as a result
thereof.

                  "FDA" - the United States Food and Drug Administration, or any
successor agency.

                  "Governmental Action" - any legislation, regulation, rule or
procedure passed, adopted or implemented after the date hereof by any federal,
state or local government, legislative body, agency (including the FDA), or
other governmental entity, or any decision, finding or action by any agency,
court or other third party which, if or when implemented, would, in the
reasonable determination of either party, (a) prevent Cytomedix from
manufacturing Procuren or otherwise performing its obligations hereunder, or (b)
prevent Curative from using Procuren at its wound treatment centers or otherwise
performing its obligations hereunder.

                  "Procuren" - Procuren(R), a thrombin-induced platelet
releasate.

                  "Procuren Costs" - the amount equal to (i) $22.49 per dose of
Procuren sold hereunder with respect to the first 275,000 doses sold to Curative
hereunder during any calendar year, and (ii) $16.25 per dose of Procuren with
respect to any additional doses sold to Curative hereunder during any calendar
year, plus fifty percent (50%) of the Facility Lease Costs amortized over a 24
month period from the date of Cytomedix's incurrence of such costs.

                  "Procuren Operations" - the development, manufacturing,
marketing, licensing and distribution of Procuren.

                  "Procuren States" - the states identified on Schedule B
attached hereto in which Curative currently distributes and sells Procuren,
excluding Oregon, Maryland, Iowa and New Hampshire, as such states may change
from time to time pursuant to the provisions herein.

                  "Technical Costs and Expenses" - the direct costs and expenses
associated with (i) quality control, quality assurance and direct corporate
support and (ii) management personnel related to the Procuren Operations.

                  "United States" - the United States of America, including any
territories or possessions thereof.

                                   ARTICLE II.
                            OBLIGATIONS OF CYTOMEDIX

                  Section 2.1 Supply of Procuren. During the Term, subject to
Section 2.2, Cytomedix shall use its Best Efforts to supply Curative with such
quantities of Procuren as to supply one hundred percent (100%) of Curative's
total requirements for Procuren in the Procuren States for use in connection
with Curative's wound care centers, all on the terms and conditions herein.

                  Section 2.2 Net Loss Procuren States.

                           (a) Notwithstanding Section 2.1, Cytomedix shall,
                  subject to Section 2.2(d) below, have no obligation to supply
                  Procuren to Curative in any Procuren State in which,

                                       2
<PAGE>

                  during any two (2) consecutive calendar quarters, Cytomedix's
                  Blood Processing Facilities Costs in connection with the
                  Procuren Operations in such state have exceeded the revenue
                  received by Cytomedix in connection with the sale of Procuren
                  to Curative in such state (such difference, the "Procuren
                  State Deficiency") (any such state, a "Net-Loss Procuren
                  State").

                           (b) Notwithstanding Section 2.1, Cytomedix shall,
                  subject to Section 2.2(e) below, have no obligation to supply
                  Procuren to Curative in any or all of the Procuren States, in
                  the event that, during any two (2) consecutive calendar
                  quarters, the sum of (i) the Blood Processing Facilities Costs
                  in the Procuren States, plus the Technical Costs and Expenses,
                  have exceeded (ii) the revenue received by Cytomedix in
                  connection with the sale of Procuren to Curative in the
                  Procuren States (such difference, the "National Deficiency")
                  (any state designated by Cytomedix pursuant to the terms of
                  this Section 2.2(b), a "Designated Net-Loss Procuren State");
                  provided, however, that Cytomedix may only designate Procuren
                  States as Designated Net-Loss Procuren States to the extent
                  that, during the previous two (2) calendar quarters, the
                  revenue received by Cytomedix from the sale of Procuren in the
                  Procuren States not designated as Designated Net-Loss Procuren
                  States does not exceed (a) the Blood Processing Costs and
                  Expenses in the Procuren States not designated as Designated
                  Net-Loss Procuren States, plus (b) the Technical Costs and
                  Expenses.

                           (c) Within thirty (30) days after the end of each
                  calendar quarter, Cytomedix shall provide Curative with
                  written notice of any Procuren State (such notice, the
                  "Net-Loss Notice") that is a Net-Loss Procuren State or a
                  Designated Net-Loss Procuren State based upon the results of
                  the previous two (2) consecutive calendar quarters, together
                  with written documentation showing the basis upon which such
                  determination has been made. At such time, Cytomedix shall
                  have no further obligation to supply Procuren to Curative in
                  such Net-Loss Procuren State or Designated Net-Loss Procuren
                  State, as the case may be, except as set forth in Sections
                  2.2(d) and 2.2(e) below; provided, however, that Cytomedix
                  shall be obligated to supply Procuren pursuant to any Orders
                  already submitted by Curative.

                           (d) Notwithstanding Section 2.2(a), Cytomedix shall
                  be obligated to continue to supply Procuren in any Net-Loss
                  Procuren State, in the event that, within fifteen (15) days of
                  Curative's receipt of the Net-Loss Notice:

                                    (i) Curative pays Cytomedix the amount of
                           the Procuren State Deficiency with respect to the two
                           (2) previous calendar quarters. In such event,
                           Cytomedix shall be obligated to supply Procuren to
                           Curative in such Net-Loss Procuren State until such
                           time, if any, that Curative elects not to pay the
                           amount of any Procuren State Deficiency with respect
                           to the two (2) previous calendar quarters (to the
                           extent not already paid by Curative pursuant to an
                           earlier Net-Loss Notice) pursuant to a subsequent
                           Net-Loss Notice; or

                                    (ii) Curative notifies Cytomedix in writing
                           that the exclusive supply obligation set forth in
                           Section 2.3 below will no longer apply with respect
                           to such Net-Loss Procuren State and that Cytomedix
                           may sell Procuren to any person in such state.

                                       3
<PAGE>

                           (e) Notwithstanding Section 2.2(b), Cytomedix shall
                  be obligated to continue to supply Procuren in any Designated
                  Net-Loss Procuren State in the event that, within fifteen (15)
                  days of Curative's receipt of the Net-Loss Notice:

                                    (i) Curative pays Cytomedix the amount of
                           the National Deficiency, with respect to the two (2)
                           previous calendar quarters. In such event, Cytomedix
                           shall be obligated to supply Procuren to Curative in
                           such Designated Net-Loss Procuren State until such
                           time, if any, that Curative elects not to pay the
                           amount of any National Deficiency with respect to the
                           two (2) previous calendar quarters (to the extent not
                           already paid by Curative pursuant to an earlier
                           Net-Loss Notice) pursuant to a subsequent Net-Loss
                           Notice; or

                                    (ii) Curative notifies Cytomedix in writing
                           that the exclusive supply obligation set forth in
                           Section 2.3 below will no longer apply with respect
                           to such Designated Net-Loss Procuren State and that
                           Cytomedix may sell Procuren to any person in such
                           state.

                           (f) Nothing contained herein to the contrary, in the
                  event that there are any consents to assignment with respect
                  to the real property leases relating to the Facilities that
                  have not been obtained at Closing (as defined in the Asset
                  Purchase Agreement) and the owner of the real property has
                  delivered a notice to vacate or similar instrument to
                  Cytomedix and Cytomedix has relocated from such Facility as
                  the result thereof, Cytomedix shall have no obligation to
                  supply Curative with Procuren in such state until such time
                  that Cytomedix is able to relocate such Facility and resume at
                  a new Facility the Procuren Operations as were previously
                  conducted.

                  Section 2.3 Exclusive Supply Obligation. During the Term,
Cytomedix shall not sell or distribute Procuren to any person in the United
States other than Curative; provided, however, that the foregoing restriction
shall not apply to the distribution of Procuren by Cytomedix to any third party
in connection with any Clinical Trial. Nothing in this Agreement restricts the
ability of Cytomedix to sell or distribute Procuren in any country other than
the United States. The provisions of this Section 2.3 shall terminate upon FDA
approval of Procuren, if any.

                  Section 2.4 Protocols. During the Term, Cytomedix shall
furnish Curative with all the necessary protocols and procedures relating to
Procuren at such time as such protocols and procedures become available.

                                  ARTICLE III.
                                     PAYMENT

                  Section 3.1 Purchase Price. The purchase price for the
Procuren (the "Purchase Price") to be supplied hereunder shall be set at the
sole discretion of Cytomedix and shall be payable as set forth in Section 3.2
below; provided, however, that prior to the receipt of FDA approval of Procuren,
if any, if the Purchase Price exceeds the Procuren Costs, Cytomedix shall rebate
such difference to Curative either by cash payment or credit against the Monthly
Charges as defined in Section 3.2 below.

                  Section 3.2 Payment. Cytomedix shall send Curative an invoice
on a monthly basis, in arrears, for the Procuren supplied to Curative and any
other expenses payable by Curative during the immediately preceding calendar
month (such amount owed by Curative, the "Monthly Charges"), together with a
report showing the calculation of the Monthly Charges for such month. Curative
shall

                                       4
<PAGE>

pay the Monthly Charges to Cytomedix within thirty (30) days of the date of
invoice therefor. If the Monthly Charges remain unpaid after thirty (30) days of
the date of invoice, interest shall accrue on such unpaid amount at the lower of
(a) fifteen percent (15%) per annum, or (b) the highest rate permitted by law,
until paid.

                  Section 3.3 Cancellation; Unsuitability for Use.

                           (a) Except as set forth in Section 3.3(b) or 3.3(c)
                  below, if Curative cancels any Order for any reason or if any
                  Procuren supplied hereunder is unsuitable for the treatment of
                  patients as the result of any action or inaction by Curative,
                  Curative shall reimburse Cytomedix for all indirect and direct
                  costs incurred by Cytomedix in connection with the manufacture
                  of such Procuren.

                           (b) If any Procuren supplied hereunder is unsuitable
                  for the treatment of patients as the result of any action or
                  inaction by Cytomedix, Curative shall have no obligation to
                  pay the Purchase Price with respect to such Procuren.

                           (c) If any Procuren supplied hereunder is unsuitable
                  for the treatment of patients and the parties are unable to
                  determine the cause of such unsuitability, Curative shall pay
                  fifty percent (50%) all indirect and direct costs incurred by
                  Cytomedix in connection with the manufacture of such Procuren.

                           (d) In any such event, any adjustment to the Purchase
                  Price shall be reflected in the invoice sent by Cytomedix to
                  Curative pursuant to Section 3.2.

                  Section 3.4 Taxes. In addition to the prices and charges
specified herein, the amount of any present or future sales, use, excise,
personal property, duty, ad valorem or similar tax or assessment (other than
taxes based on Cytomedix's net income) applicable to the sale of the Procuren
hereunder to Curative shall be paid by Curative when due. If Curative is exempt
from sales tax by its status as a distributor, Curative shall provide evidence
of a sales tax exemption certificate or reseller's registration number.

                                   ARTICLE IV.
                                ORDERS; DELIVERY

                  Section 4.1 Orders. Curative shall initiate all orders of
Procuren by submitting a written order (the "Order") to Cytomedix for the
purchase of Procuren which shall specify or contain (a) the quantity of units to
be purchased, (b) the scheduled delivery date (which shall in no event be a date
earlier than fourteen (14) days from the date the blood of the patient necessary
for the manufacture of Procuren is received by Cytomedix or such other time
period as set forth in Exhibit 5.1 hereof), (c) the address for shipment, and
(d) such other information reasonably requested by Cytomedix, together with
sufficient quantities of the blood of the patient necessary for the manufacture
of Procuren. In all such cases, such blood shall be shipped by Curative to
Cytomedix according to the instructions of Cytomedix.

                  Section 4.2 Delivery of Procuren. Within fourteen (14) days
from the date the blood of the patient necessary for the manufacture of Procuren
is received by Cytomedix or such other time period as set forth in Exhibit 5.1
hereof, Cytomedix shall deliver Procuren to the address specified in the Order
along with the Procuren Release Test Results, substantially in the form attached
hereto as Exhibit 4.2. Curative shall be notified of such shipment and shall be
provided with the name of the common carrier and the package tracking number.
Freight charges shall be paid by Cytomedix. Title and risk of

                                       5
<PAGE>

loss with respect to the Procuren supplied hereunder shall pass to Curative at
the point of delivery at the address specified in the Order. In the event
Cytomedix fails to deliver Procuren within the time period set forth above and
the Procuren is unsuitable for treatment as the result of such delay or if any
Procuren supplied by Cytomedix is otherwise unsuitable for treatment as the
result of any action or inaction by Cytomedix, (a) Curative shall have no
obligation to pay the Purchase Price in connection with the Order of such
Procuren as set forth in Section 3.3(b), and (b) if Curative submits another
Order for the same patient, Cytomedix shall promptly redeliver Procuren with
respect to such patient for the Purchase Price and on the other terms and
conditions herein. Cytomedix's obligation to redeliver Procuren as set forth
above shall be Curative's sole remedy in the event any Procuren supplied
hereunder is unsuitable for treatment as the result of any late delivery or
other action or inaction by Cytomedix.

                  Section 4.3 Notification. Each party shall provide the other
party with notice of any adverse experience involving Procuren resulting in
serious injury or death as soon as possible but in any event within twenty-four
(24) hours after such party receives notice of such occurrence, whether in the
United States or any foreign country, and whether sold by such party or any
third party.

                  Section 4.4 Transportation of Blood and Procuren. Curative
acknowledges and agrees that until such time, if any, that Procuren receives FDA
approval (or such earlier time that Cytomedix provides written notice that the
restrictions of this Section 4.4 no longer apply), Curative shall not transport
Procuren across the border of any state for any reason whatsoever.

                  Section 4.5 Product Labeling. In order to comply with
applicable law and in order to protect Cytomedix from claims and liabilities,
Curative's communications and representations to customers shall be true,
accurate, complete and consistent with the labeling of Procuren. Curative shall
not modify, repackage, adulterate, misbrand, alter or add labels to or remove
labels from any Procuren without the prior written approval of Cytomedix.

                                   ARTICLE V.
                         REPRESENTATIONS AND WARRANTIES

                  Section 5.1 Representations and Warranties of Cytomedix.
Cytomedix represents and warrants that the Procuren to be supplied hereunder
will be manufactured in accordance with the specifications set forth in Exhibit
5.1 attached hereto, as it may be amended from time to time.

                  Section 5.2 Limitation of Warranty. EXCEPT AS SET FORTH IN
SECTION 5.1 ABOVE, CYTOMEDIX MAKES NO EXPRESS OR IMPLIED WARRANTIES OR
REPRESENTATIONS WITH RESPECT TO THE PROCUREN TO BE SUPPLIED HEREUNDER OR
OTHERWISE IN CONNECTION WITH THIS AGREEMENT, INCLUDING ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY WARRANTY RELATING TO
THE EFFICACY OF PROCUREN OR ANY WARRANTY OF NONINFRINGEMENT OF THE RIGHTS OF ANY
THIRD PARTY, AND ALL SUCH WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED. CYTOMEDIX
MAKES NO WARRANTY, EXPRESS OR IMPLIED, TO ANY PERSON OR ENTITY OTHER THAN
CURATIVE CONCERNING PROCUREN. CURATIVE ACKNOWLEDGES THAT THIS LIMITATION OF
WARRANTY IS A MATERIAL INDUCEMENT FOR CYTOMEDIX TO ENTER INTO THIS AGREEMENT.

                  Section 5.3 Survival. The provisions of this Article V shall
survive the termination of this Agreement.

                                       6
<PAGE>

                                   ARTICLE VI.
                                 CONFIDENTIALITY

                  Each party acknowledges that any information concerning the
other party received in connection with this Agreement shall be deemed
"Confidential and Proprietary Information" (provided that information contained
within the Assets (as defined in the Asset Purchase Agreement) transferred to
Cytomedix shall not be deemed Confidential and Proprietary Information of
Curative). Except as otherwise set forth herein, each party agrees that it shall
not permit the duplication, use or disclosure of any such Confidential and
Proprietary Information to any person or entity (other than its own employees or
agents who must have such information for any proper purpose), unless (a)
authorized in writing and signed by the other party, or (b) legally required to
disclose such information, provided that the party availing itself of this
exception has promptly notified the other party of such required disclosure and
has used commercially reasonable efforts to lawfully avoid or limit such
disclosure. Confidential and Proprietary Information does not include any
information which, at the time of disclosure, is generally known by the public
through no breach of the disclosing party. The provisions of this Article VI
survive the expiration or termination of this Agreement.

                                  ARTICLE VII.
                                    INSURANCE

                  During the Term, each party shall, at its sole cost and
expense, maintain Comprehensive Public General Liability Insurance, including
contractual liability, product liability, and personal injury coverage, with a
minimum combined single limit of $1,000,000 per occurrence, $3,000,000 per year,
and naming the other party as an additional insured. Each party shall provide
the other party with a Certificate of Insurance evidencing such coverage upon
request thereof by such party. Each party shall give the other party at least
thirty (30) days' prior written notice of the expiration or cancellation of, or
any material change in, any insurance policy required to be maintained by such
party pursuant to the terms of this Agreement.

                                 ARTICLE VIII.
                               RECORDS AND AUDITS

                  Section 8.1 Maintenance of Records by Curative; Audits.

                           (a) Curative shall maintain (i) full and accurate
                  books and records in connection with the performance of its
                  duties hereunder, including a record of the locations at which
                  Procuren is utilized, and (ii) full and accurate patient
                  records in connection with the usage of Procuren at any wound
                  treatment centers of Curative (the "Patient Data"). All such
                  books and records shall be kept and maintained for at least
                  the greater of (1) three (3) years after the termination of
                  this Agreement, or (2) the minimum amount of time required by
                  law. Cytomedix shall have the right, during Curative's
                  business hours upon reasonable prior notice to Curative, to
                  inspect any of the books and records referenced above,
                  including the Patient Data, subject to any applicable laws.
                  Cytomedix shall have the right to access and use the Patient
                  Data for any lawful purpose, including getting data to support
                  any necessary filings with the FDA, subject to any applicable
                  laws.

                           (b) Cytomedix shall be entitled to conduct an audit,
                  from time to time, of Curative's methods and procedures in
                  connection with the blood product supplied by Curative for the
                  manufacture of Procuren to assure compliance with this
                  Agreement and

                                       7
<PAGE>

                  product specifications. Cytomedix may engage an independent
                  third party auditor to conduct such audits. Curative shall
                  cooperate with Cytomedix and its designated auditor in the
                  performance of such audits and shall take prompt and
                  appropriate action to correct any deficiencies discovered by
                  Cytomedix or its auditor. Curative shall be entitled to
                  receive a copy of any audit reports produced by or on behalf
                  of Cytomedix hereunder.

                  Section 8.2 Maintenance of Records by Cytomedix; Audits.

                           (a) Cytomedix shall maintain full and accurate books
                  and records in connection with the performance of its duties
                  hereunder. All such books and records shall be kept and
                  maintained for at least the greater of (a) three (3) years
                  after the termination of this Agreement, or (b) the minimum
                  amount of time required by law. Curative shall have the right,
                  during Cytomedix's business hours upon reasonable prior notice
                  to Cytomedix, to inspect any of the books and records
                  referenced above, subject to any applicable laws.

                           (b) Until such time, if any, that Procuren receives
                  FDA approval, Curative shall be entitled to conduct an audit,
                  from time to time, of Cytomedix's methods and procedures in
                  connection with the manufacture of Procuren hereunder to
                  assure compliance with this Agreement and product
                  specifications. Curative may engage an independent third party
                  auditor to conduct such audits. Cytomedix shall cooperate with
                  Curative and its designated auditor in the performance of such
                  audits and shall take prompt and appropriate action to correct
                  any deficiencies discovered by Curative or its auditor.
                  Cytomedix shall be entitled to receive a copy of any audit
                  reports produced by or on behalf of Curative hereunder.

                                   ARTICLE IX.
                                  IMPROVEMENTS

                  Section 9.1 Definition. For the purposes of this Article IX,
"Improvements" shall mean any development, enhancement, or modification in the
Procuren product or its process for manufacturing that arises on or after the
Effective Date and results from the work of any employee or consultant of
Curative.

                  Section 9.2 Title to Improvements. Cytomedix shall have the
right, but not the obligation, to take Curative's right, title and interest in
and to any Improvements, whereupon the same, as more specifically set forth in
Section 9.3 below, shall be incorporated into the definition of Procuren patents
and know-how included within the Assets (as defined in the Asset Purchase
Agreement) transferred to Cytomedix under the Asset Purchase Agreement. Curative
shall fully disclose any such Improvements to Cytomedix in writing within sixty
(60) days after their actual or constructive reduction to practice. The writing
shall include, if appropriate and without limitation, any drawings, laboratory
notes, methods, processes, samples, materials and specification in Curative's
possession or control. Curative shall promptly respond and assist Cytomedix or
any of its attorneys responsible for evaluating the patentability of such
Improvements and shall make available, at no cost to Curative, knowledgeable
persons, including without limitation, the inventor, to consult with Cytomedix
regarding the nature and details of all Improvements.

                  Section 9.3 Notification by Cytomedix. Cytomedix shall, upon
receipt of any written notice from Curative pursuant to Section 9.2, notify
Curative whether Cytomedix desires to take Curative's right, title and interest
in and to such Improvements. If so, any such Improvements that

                                       8
<PAGE>

constitute, in Cytomedix's sole discretion, patentable inventions shall
thereupon be incorporated into the definition of Procuren patents included
within the Assets transferred to Cytomedix under the Asset Purchase Agreement,
provided that Cytomedix, within one (1) year or such longer period consented to
by Curative (which consent shall not be unreasonably withheld), files an
application for one (1) or more U.S. and/or foreign patents and thereafter in
good faith prosecutes and, if one or more patents are issued, maintains, patent
protection in respect to such Improvements. Any Improvements that do not, in
Cytomedix's sole discretion, constitute patentable inventions shall be
incorporated into the definition of know-how included within the Assets
transferred to Cytomedix under the Asset Purchase Agreement. Curative shall
execute any necessary documents and cooperate in good faith to the extent that
Cytomedix may reasonably require in order to enable Cytomedix to fully enforce
and exercise its rights to such Improvements. During the time allowed for filing
an application for a U.S. and/or foreign patent with respect to any
Improvements, Curative shall refrain from any activity, including without
limitation, the sale, offer for sale, public use, or disclosure of said
Improvements, that could foreseeably cause forfeiture of patent rights therein.

                                   ARTICLE X.
                             LIMITATION OF LIABILITY

                  Section 10.1 Limitation on Types of Damages. NOTWITHSTANDING
ANY PROVISION OF THIS AGREEMENT TO THE CONTRARY, NEITHER PARTY SHALL BE LIABLE
TO THE OTHER PARTY FOR ANY SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE OR
CONSEQUENTIAL DAMAGES, WHETHER FORESEEABLE OR NOT, ARISING OUT OF, OR IN
CONNECTION WITH SUCH PARTY'S FAILURE TO PERFORM ITS RESPECTIVE OBLIGATIONS OR
BREACH OF ITS RESPECTIVE REPRESENTATIONS HEREUNDER.

                  Section 10.2 Limitation on Amount of Damages. IN NO EVENT
SHALL CYTOMEDIX BE LIABLE TO CURATIVE IN CONNECTION WITH THIS AGREEMENT IN AN
AGGREGATE AMOUNT THAT EXCEEDS THE TOTAL AMOUNT PAID BY CURATIVE TO CYTOMEDIX
PURSUANT TO THE TERMS HEREIN.

                  Section 10.3 Survival. The provisions of this Article X
survive the expiration or termination of this Agreement.

                                   ARTICLE XI.
                                 INDEMNIFICATION

                  Section 11.1 Indemnification by Curative. Subject to Article
X, Curative shall fully defend and hold Cytomedix and its Affiliates, and their
respective directors, stockholders, employees, officers and agents harmless from
any and all claims, demands, damages, liabilities, costs or expenses (including
attorneys' fees and expenses) arising out of or in connection with (a) the
negligent, reckless or intentional acts or omissions of Curative or its agents,
or (b) the breach by Curative of any representation, warranty, covenant or
obligation in this Agreement.

                  Section 11.2 Indemnification by Cytomedix. Subject to Article
X, Cytomedix shall fully defend and hold Curative and its Affiliates, and their
respective directors, stockholders, employees, officers and agents harmless from
any and all claims, demands, damages, liabilities, costs or expenses (including
attorneys' fees and expenses) arising out of or in connection with (a) the
negligent, reckless or intentional acts or omissions of Cytomedix or its agents,
or (b) the breach by Cytomedix of any representation, warranty, covenant or
obligation in this Agreement.

                                       9
<PAGE>

                  Section 11.3 Procedure for Indemnification - Third Party
Claims.

                           (a) Promptly after receipt by an indemnified party
                  under Section 11.1 or 11.2 of notice of the commencement of
                  any proceeding ("Proceeding") against it by a third party,
                  such indemnified party shall, if a claim is to be made against
                  an indemnifying party under such Sections, give notice to the
                  indemnifying party of the commencement of such Proceeding, but
                  the failure to notify the indemnifying party does not relieve
                  the indemnifying party of any liability that it may have to
                  any indemnified party, except to the extent that the
                  indemnifying party demonstrates that the defense of such
                  action is prejudiced by the indemnified party's failure to
                  give such notice.

                           (b) If an indemnified party gives notice to the
                  indemnifying party of the commencement of a Proceeding
                  referred to in Section 11.3(a), the indemnifying party is
                  entitled to participate in such Proceeding and, to the extent
                  that it wishes to assume the defense of such Proceeding with
                  counsel satisfactory to the indemnified party and, after
                  notice from the indemnifying party to the indemnified party of
                  its election to assume the defense of such Proceeding, the
                  indemnifying party is not, as long as it diligently conducts
                  such defense, liable to the indemnified party under this
                  Article XI for any fees of other counsel or any other expenses
                  with respect to the defense of such Proceeding, in each case
                  subsequently incurred by the indemnified party in connection
                  with the defense of such Proceeding, other than reasonable
                  costs of investigation (unless (i) the indemnifying party is
                  also a party to such Proceeding and the indemnified party
                  determines in good faith that joint representation would be
                  inappropriate, or (ii) the indemnifying party fails to provide
                  reasonable assurance to the indemnified party of its financial
                  capacity to defend such Proceeding and provide indemnification
                  with respect to such Proceeding). If the indemnifying party
                  assumes the defense of a Proceeding, (x) it will be
                  conclusively established for purposes of this Agreement that
                  the claims made in that Proceeding are within the scope of and
                  subject to indemnification; (y) no compromise or settlement of
                  such claims may be effected by the indemnifying party without
                  the indemnified party's consent unless (A) there is no finding
                  or admission of any violation of legal requirements or any
                  violation of the rights of any person and no effect on any
                  other claims that may be made against the indemnified party,
                  and (B) the sole relief provided is monetary damages that are
                  paid in full by the indemnifying party; and (z) the
                  indemnified party will have no liability with respect to any
                  compromise or settlement of such claims effected without its
                  consent. If notice is given to an indemnifying party of the
                  commencement of any Proceeding and the indemnifying party does
                  not, within ten (10) days after the indemnified party's notice
                  is given, give notice to the indemnified party of its election
                  to assume the defense of such Proceeding, the indemnifying
                  party will be bound by any determination made in such
                  Proceeding or any compromise or settlement effected by the
                  indemnified party.

                           (c) Notwithstanding the foregoing, if an indemnified
                  party determines in good faith that there is a reasonable
                  probability that a Proceeding may adversely affect it other
                  than as a result of monetary damages for which it would be
                  entitled to indemnification under this Agreement, the
                  indemnified party may, by notice to the indemnifying party,
                  assume the exclusive right to defend, compromise, or settle
                  such Proceeding, but the indemnifying party will not be bound
                  by any determination of a Proceeding so defended for the
                  purposes of this Agreement or any compromise or settlement
                  effected without its consent (which may not be unreasonably
                  withheld).

                                       10
<PAGE>

                  Section 11.4 Procedure For Indemnification - Other Claims. A
claim for indemnification for any matter not involving a third-party claim may
be asserted by notice to the party from whom indemnification is sought.

                  Section 11.5 Survival. The provisions of this Article XI
survive the expiration or termination of this Agreement.

                                  ARTICLE XII.
                              TERM AND TERMINATION

                  Section 12.1 Term. Unless earlier terminated pursuant to
Sections 12.2 or 12.3 below, this Agreement commences upon the Effective Date
and terminates upon Cytomedix's written notice to Curative of the occurrence of
a Triggering Event (such period, the "Term"). For purposes of this Section 12.1,
a "Triggering Event" constitutes any reasonable determination by Cytomedix that
FDA approval of Procuren is not likely to be obtained. Notwithstanding the
foregoing, upon the receipt of FDA approval of Procuren, if any, the Term
extends for a period of one (1) year from the date of FDA approval and
thereafter may be extended for successive terms of one (1) year each upon the
mutual consent of the parties hereto.

                  Section 12.2 Termination by Cytomedix. Cytomedix may terminate
this Agreement:

                           (a) If Curative fails to pay any amounts owed
                  hereunder when due and does not cure such non-payment within
                  thirty (30) days thereof; or

                           (b) Upon thirty (30) days' prior written notice to
                  Curative, if Curative breaches any of its other material
                  obligations hereunder and fails to cure such breach by the end
                  of such thirty (30) day period.

                  Section 12.3 Termination by Curative. Curative may terminate
this Agreement upon thirty (30) days' prior written notice to Cytomedix, if
Cytomedix breaches any of its other material obligations hereunder and fails to
cure such breach by the end of such thirty (30) day period. In addition,
Curative may terminate this Agreement for any reason upon ninety (90) days'
prior written notice to Cytomedix.

                  Section 12.4 Termination or Modification in the Event of
Governmental Action. If the parties receive notice of any Governmental Action,
the parties shall attempt in good faith to amend this Agreement in order to
comply with the Governmental Action. If the parties, acting in good faith, are
unable to agree to amendments necessary to comply with the Governmental Action
or if the parties determine in good faith that compliance with the Governmental
Action is impossible or unfeasible, this Agreement shall terminate at the end of
ten (10) days after written notice thereof by either party. Neither party shall
be in breach of this Agreement or liable to the other party as the result of the
termination of this Agreement pursuant to this Section 12.4. In addition,
nothing contained herein to the contrary, Cytomedix shall have no obligation to
supply Procuren to Curative in, and this Agreement shall otherwise terminate
with respect to, any Procuren State in which (a) Cytomedix determines in good
faith that it is impossible or unfeasible to supply Procuren to Curative
hereunder as the result of any Governmental Action or (b) Cytomedix otherwise
determines in good faith that the continued operation of the Procuren Operations
therein would result in Cytomedix being in violation of any applicable law,
regulation, rule or other legal requirement applicable to it. Cytomedix shall
promptly notify Curative of such determination with respect to any Procuren
State.

                                       11
<PAGE>

                  Section 12.5 Remedies upon Termination. Termination of this
Agreement shall not limit either party from pursuing any other remedies
otherwise available to it, including, without limitation, injunctive relief.

                  Section 12.6 Effect of Termination. In the event of notice of
termination, each party shall continue to perform its obligations hereunder up
to the date of termination. Upon termination, except as otherwise provided
herein, the obligations of the parties hereunder shall cease; provided, however,
that Cytomedix shall be obligated to supply Procuren pursuant to any Orders
received by Cytomedix prior to the date of termination. Following termination of
this Agreement, Curative shall promptly pay Cytomedix any money then due and
owing upon receipt of invoice therefor.

                                  ARTICLE XIII.
                                  MISCELLANEOUS

                  Section 13.1 Force Majeure. Neither party shall be in default
by reason of any failure in performance of this Agreement if such failure arises
out of causes beyond the control of such nonperforming party, including, but not
restricted to, acts of God, acts of government, insurrections, fires, floods,
accidents, epidemics, quarantines, restrictions, strikes, freight embargoes,
inability to secure materials or transportation facilities, or any and all other
causes beyond the party's reasonable control.

                  Section 13.2 No Joint Venture. Nothing herein shall create any
association, partnership, joint venture or agency relationship between the
parties hereto or any third party.

                  Section 13.3 Further Assurances. The parties shall cooperate
reasonably with each other in connection with any steps required to be taken as
part of their respective obligations under this Agreement, and the parties agree
(a) to furnish upon request to each other such further information, (b) to
execute and deliver to each other such other documents, and (c) to do such other
acts and things, all as the other party may reasonably request for the purpose
of carrying out the intent of this Agreement.

                  Section 13.4 Compliance with Legal Requirements.

                           (a) Curative covenants that it shall comply in all
                  material respects with all Federal, state or local laws,
                  regulations, ordinances or other legal requirements in
                  connection with the transportation, storage, use, resale and
                  disposal of Procuren and the performance of its duties
                  hereunder.

                           (b) Cytomedix covenants that it shall comply in all
                  material respects with all Federal, state or local laws,
                  regulations, ordinances or other legal requirements in
                  connection with the storage and manufacture of Procuren and
                  the performance of its duties hereunder.

                  Section 13.5 Notices. All notices, consents, waivers, and
other communications under this Agreement must be in writing and are deemed to
have been duly given when (a) delivered by hand with written confirmation of
receipt, (b) sent by facsimile with confirmation of transmission by the
transmitting equipment, (c) five (5) days after delivery, if sent by certified
mail, return receipt requested, or (d) one (1) day after delivery, if sent by a
nationally recognized overnight delivery service, return receipt requested, in
each case to the appropriate addresses, or facsimile numbers set forth below (or
to such other addresses, facsimile numbers or as a party may designate by notice
to the other parties):

                                       12
<PAGE>

           Cytomedix:        Cytomedix, Inc.
                             Three Parkway North
                             Deerfield, Illinois 60015
                             Attention: Christopher J. Caywood
                             Vice President of Strategy and Business Development
                             Fax: (847) 405-7801

           with a copy to:   Latham & Watkins
                             1001 Pennsylvania Ave., N.W.
                             Suite 1300
                             Washington, D.C. 20004
                             Attention: Stuart S. Kurlander, Esq.
                             Fax: (202) 637-2201

           Curative:         Curative Health Services, Inc.
                             150 Motor Parkway
                             Hauppauge, New York 11788
                             Attention:  William Tella
                             Sr. Vice President of Business Development
                             Fax: (631) 233-8107

           with a copy to:   Dorsey & Whitney LLP
                             250 Park Avenue
                             New York, New York 10177
                             Attention: Seth I. Truwit, Esq.
                             Fax: (212) 953-7201

                  Section 13.6 Waiver. The rights and remedies of the parties to
this Agreement are cumulative and not alternative. Neither the failure nor any
delay by any party in exercising any right under this Agreement operates as a
waiver of such right, and no single or partial exercise of any such right
precludes any other or further exercise of such right or the exercise of any
other right. To the maximum extent permitted by applicable law, (a) no claim or
right arising out of this Agreement can be discharged by one party, in whole or
in part, by a waiver or renunciation of the claim or right unless in writing
signed by the other party; (b) no waiver that may be given by a party will be
applicable except in the specific instance for which it is given; and (c) no
notice to or demand on one party will be deemed to be a waiver of any obligation
of such party or of the right of the party giving such notice or demand to take
further action without notice or demand as provided in this Agreement.

                  Section 13.7 Entire Agreement and Modification. This Agreement
and the Asset Purchase Agreement constitute the entire agreement between the
parties with respect to the subject matter of this Agreement and supersede all
prior written and oral agreements and understandings between the parties with
respect to the subject matter of this Agreement. This Agreement may not be
amended except by a written agreement signed on behalf of each of the parties
hereto.

                  Section 13.8 Assignment. No party to this Agreement may
assign, transfer, or otherwise dispose of any of its rights, duties, or
obligations hereunder without the prior written consent of the other party
hereto; provided, however, that (a) either party may assign, transfer, or
otherwise dispose of any of its rights, duties or obligations hereunder to any
of its Affiliates without the prior consent of the other party, and (b)
Cytomedix may subcontract any of its manufacturing obligations

                                       13
<PAGE>

hereunder (provided that in any such case the assigning or subcontracting party
shall continue to be liable for its obligations hereunder), provided that no
such assignment or delegation pursuant to clauses (a) or (b) shall relieve
either party from any of its obligations hereunder. Subject to the foregoing,
this Agreement shall be binding upon and shall inure to the benefit of the
parties hereto and their permitted successors and assigns.

                  Section 13.9 Severability. If any provision of this Agreement
is held invalid or unenforceable by any court of competent jurisdiction, the
other provisions of this Agreement remain in full force and effect. The parties
further agree that if any provision contained herein is, to any extent, held
invalid or unenforceable in any respect under the laws governing this Agreement,
they shall take any actions necessary to render the remaining provisions of this
Agreement valid and enforceable to the fullest extent permitted by law and, to
the extent necessary, shall amend or otherwise modify this Agreement to replace
any provision contained herein that is held invalid or unenforceable with a
valid and enforceable provision giving effect to the intent of the parties.

                  Section 13.10 No Third Party Beneficiary. No provision of this
Agreement shall create, or be deemed to create, any legal or equitable right in
any person not a party to this Agreement or give any such person any claim
against any party to this Agreement that such party would not have but for this
Agreement.

                  Section 13.11 Section Headings; Construction. The headings of
Articles and Sections in this Agreement are provided for convenience only and
will not affect its construction or interpretation. All words used in this
Agreement will be construed to be of such gender or number as the context
requires. The language used in the Agreement shall be construed, in all cases,
according to its fair meaning, and not for or against any party hereto. The
parties acknowledge that each party has reviewed this Agreement and that rules
of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be available in the interpretation of this
Agreement.

                  Section 13.12 Governing Law; Jurisdiction. This Agreement is
to be governed by and construed under the laws of the State of New York without
regard to conflicts of laws principles that would require the application of any
other law. The parties agree that the state and federal courts located in New
York County, New York, shall be the sole venue and shall have sole jurisdiction
for the resolution of all disputes arising hereunder.

                  Section 13.13 Execution of Agreement, Counterparts. This
Agreement may be executed in one or more counterparts, each of which will be
deemed to be an original copy of this Agreement and all of which, when taken
together, will be deemed to constitute one and the same agreement. The exchange
of copies of this Agreement and of signature pages by facsimile transmission
shall constitute effective execution and delivery of this Agreement as to the
parties and may be used in lieu of the original Agreement for all purposes.
Signatures of the parties transmitted by facsimile shall be deemed to be their
original signatures for any purpose whatsoever.

                  [remainder of page intentionally left blank]

                                       14
<PAGE>

                      [signature page to Supply Agreement]

                  IN WITNESS WHEREOF, the parties have executed this Agreement
as of the date first written above.

                              CYTOMEDIX:
                              CYTOMEDIX, INC.

                              By:   /s/ illegible
                                   --------------------------------------------
                              Name: Christopher Caywood
                                   --------------------------------------------
                              Its:  Vice President
                                   --------------------------------------------

                              CURATIVE:
                              CURATIVE HEALTH SERVICES, INC.

                              By:   /s/ William C. Tella
                                   --------------------------------------------
                              Name: William C. Tella
                                   --------------------------------------------
                              Its:  Senior Vice President, Business Development
                                   --------------------------------------------

                                       15
<PAGE>

                                   SCHEDULE A

                                   FACILITIES

ALABAMA
Physician's Plaza #2, 3rd Floor
1424 North Carraway Blvd.
Birmingham

CALIFORNIA
6083 Bristol Parkway Suite 1400
Culver City

COLORADO
Arrow Plaza 1250 S. Hover Road Suite B,
Longmont, Boulder County

CONNECTICUT
419 West Avenue
Stamford

DELAWARE
Riverside Medical Arts Complex
700 Lea Blvd, Suite 305
Wilmington

FLORIDA
Suites F-8, 9 & 10 Quorum
Center/ Orlando, 4303
Vineland Road, Orlando

GEORGIA
200 Atlanta Technology Center
Suite 235, 1575
Northside Dr., Atlanta

ILLINOIS
1960 Springer Drive
Lombard

INDIANA
Rm. A-7, Interstate
Shopping Center
2408 Interstate Plaza Drive,
Hammond

                                        i
<PAGE>

KANSAS
P/O Bldg.#17
8240 Marshal Drive
Brookhollow Business
Park, Lenexa

KENTUCKY
Suite 700, Blanken-baker
Business Center II
Blankenbaker Crossing, Louisville

LOUISIANA
1720 Oak Park Blvd.
Lake Charles

MASSACHUSETTS
211 Park Street, P.O. Box 2963
Attleboro

MICHIGAN
Suite 130, Kirts
Medical Bldg.
1350 Kirtz, Troy

MISSISSIPPI
Suit 102D, 220
Business Plaza, 102
Business Park Drive
Jackson

MISSOURI
Suite 638, Colonnade
Building, 638-680
Office Parkway, Creve Coeur

NEBRASKA
744 O street
Lincoln

NEW JERSEY
Union Plaza Shopping
Center, 2441A Route
22 West, Union

NEW YORK
Suites LL101 and 102, p/o
Lower Level, 88 Sunnyside
Blvd., Plainview

NORTH CAROLINA

                                       ii
<PAGE>

625-105 Hutton Street
Pylon Commercial Park
Raleigh

OHIO
Suite C, Henthorne
Professional Bldg.,
1574 Henthorne Dr.
Maumee

OKLAHOMA
Suite 105 Broadway
Tech Center, 7508
North Broadway, Oklahoma City

PENNSYLVANIA
Unit B, 3448 Progress
Drive, Bensalem

PUERTO RICO
P.O. Box 1910 Avenida
Las Americas, Ponce

RHODE ISLAND
P/O Lower Level,
640 George Washington
Highway, Lincoln

SOUTH CAROLINA
Suite 412, 104 Corporate
Blvd., West Columbia

TENNESSEE
Aspen Grove Flex Center I,
318 Seaboard Lane
Suite 105, Franklin

TEXAS
7071B Twin Hills
Dallas

WASHINGTON
P/O Bldg. 19
935 Powell Ave., SW
Renton

                                      iii

<PAGE>

WEST VIRGINIA
Entire 1st Floor
3508 Staunton Ave.
Charleston

                                       iv

<PAGE>

                                   SCHEDULE B

                                 PROCUREN STATES

Alabama
California
Colorado
Connecticut
Delaware
Florida
Georgia
Illinois
Indiana
Kansas
Kentucky
Louisiana
Massachusetts
Michigan
Mississippi
Missouri
Nebraska
New Jersey
New York
North Carolina
Ohio
Oklahoma
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
Tennessee
Texas
Washington
West Virginia

                                       v

<PAGE>

                                   EXHIBIT 4.2

                          PROCUREN RELEASE TEST RESULTS

                                    [omitted]

This exhibit has been omitted from this report in accordance with Item 601 of
Regulation S-K. The Registrant hereby agrees to furnish supplementally to the
Securities and Exchange Commission a copy of this exhibit upon request.

                                       vi

<PAGE>

                                   EXHIBIT 5.1

                          MANUFACTURING SPECIFICATIONS

                                    [omitted]

This exhibit has been omitted from this report in accordance with Item 601 of
Regulation S-K. The Registrant hereby agrees to furnish supplementally to the
Securities and Exchange Commission a copy of this exhibit upon request.

                                      vii

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}]]